PureIMS aims to find a partner for its lead program Levodopa Cyclops™ Roden — December 22, 2021 — PureIMS today announced that it is participating in Biotech Showcase™ 2022. PureIMS is a clinical stage pharmaceutical and medication systems company developing a portfolio of products addressing acute and unmet medical needs. These products are based on […]

PureIMS preparing for Series A financing round aiming to bring its two lead programs to marketing authorization Roden — December 16, 2020 — PureIMS today announced that it is participating in Biotech Showcase™ Digital 2021, and providing an on-demand company presentation. Bram van Dijck, CEO, will be presenting PureIMS at Biotech Showcase Digital. PureIMS is […]

Delivery via inhaler could dramatically expand Amikacin’s clinical utility by immediate reduction of the contagiousness of Mycobacterium tuberculosis. Roden — July 1st, 2020 — PureIMS, a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory and systemic diseases, announces today the initiation of a Phase 1 clinical trial to evaluate the […]

In the fight against COVID-19, PIMS Hydroxychloroquine (subsidiary of PureIMS) – together with (among others) the University of Groningen, UMCG and IMDS – is working feverishly on inhaled hydroxychloroquine. Following pulmonary administration, we expect a much greater effect of the drug with a lower chance of side effects, because it is administered directly to the […]

In a joint effort with UMCG, University of Groningen and several international partners, PureIMS is actively battling the COVID-19 pandemic by repurposing hydroxychloroquine for pulmonary administration. A first in man trial with Hydroxychloroquine Cyclops™ is in preparation. Nevertheless, it will take months if not longer before this product will become available, if proven effective. We are […]